For the first time, this study showed that consolidation therapy with a PD-L1 inhibitor (durvalumab) in combination with a CD73 inhibitor (oleclumab) further improved the clinical outcomes in patients with unresectable stage III NSCLC after radiotherapy. Here, NT5E is linked to non-small cell lung carcinoma.